title: Effects of three cytokine regimens on hematologic recovery and progenitor cell mobilization after high-dose cyclophosphamide, etoposide, and cisplatin.
abstract: The aim of this study was to compare both the effects on hematologic recovery and circulating progenitor cell mobilization and the toxicity of three cytokine regimens administered after high-dose non-myeloablative chemotherapy with cyclophosphamide 5 g/m(2), etoposide 1.5 g/m(2) and cisplatin 150 mg/m(2). Thirty-five consecutive patients were non-random sequentially allocated to one of three treatment groups: (1) granulocyte colony-stimulating factor alone (n = 15); (2) granulocyte-macrophage colony-stimulating factor alone (n = 10), and (3) sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor (n = 10). Neutrophil recovery in group 1 was significantly hastened as compared to the two other groups (median 2 days, p < 0.005), while no significant differences were observed between groups 2 and 3. CD34+ cells peaked about 2 days earlier in group 1 compared to the other groups (p = 0.0001), whereas the median peak value of CD34+ cells was similar in the three groups. In all patients, the toxicity related to cytokine administration was low and easily manageable with nonsteroidal anti-inflammatory drugs.
authors.affiliation: Dipartimento di Medicine Interna, Università di Genova, Genova, Italia.
authors.forename: A
authors.initials: A
authors.lastname: Ballestrero
authors.forename: F
authors.initials: F
authors.lastname: Ferrando
authors.forename: A
authors.initials: A
authors.lastname: Garuti
authors.forename: R
authors.initials: R
authors.lastname: Gonella
authors.forename: P
authors.initials: P
authors.lastname: Stura
authors.forename: M
authors.initials: M
authors.lastname: Sessarego
authors.forename: D
authors.initials: D
authors.lastname: Amoroso
authors.forename: F
authors.initials: F
authors.lastname: Boccardo
authors.forename: F
authors.initials: F
authors.lastname: Patrone
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D016207:Cytokines / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D007377:Interleukin-3 / Q000008:administration & dosage; D007958:Leukocyte Count; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*; D013921:Thrombocytopenia / Q000517:prevention & control*
chemical_list: D018952:Antigens, CD34; D016207:Cytokines; D007377:Interleukin-3; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide; D002945:Cisplatin